A study led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) has developed a new pharmacological tool capable of simultaneously administering three oligonucleotide-based drugs, each acting against a different therapeutic target within the cell. The paper, published in the journal Bioorganic Chemistry , presents a proof-of-concept of this innovative triple-targeting compound, which has been successfully applied to breast cancer cells. According to the researchers, it is a therapy with "high potential for the treatment of complex diseases such as cancer or diabetes".
The study is led by Professor Montserrat Terrazas, from the UB's Department of Inorganic and Organic Chemistry of the Faculty of Chemistry, and by Sandra Pérez-Torras, lecturer at the Department of Biochemistry and Molecular Biomedicine of the UB's Faculty of Biology and researcher at the Centre for Biomedical Research Network on Liver and Digestive Diseases (CIBEREHD) and the Sant Joan de Déu Research Institute (IRSJD). Professor Marçal Pastor Anglada has also participated and postdoctoral researcher Aida Mata-Ventosa and predoctoral researcher Ariadna Vila-Planas have taken part as first authors of the scientific article. New strategy against drug resistance Multifactorial or complex pathologies, such as cancer, are the result of the joint action of multiple factors in the body, which activate different tumor signalling pathways.
This multiplicity of signals makes cancer .